Formation Bio described an AI‑native development model that combines in‑licensed assets and a centralized data‑driven development engine to speed clinical execution and cut costs. CTO Dan Neil outlined the hub‑and‑spoke approach and said the company has raised more than $600 million to apply platform efficiencies across multiple assets. Insilico Medicine bolstered its clinical leadership by hiring Dr. Halle Zhang as VP of Clinical Development for Oncology, signaling AI‑first discovery firms are investing in traditional clinical expertise to translate models into registrational programs. The moves reflect a maturing AI+biotech strategy that pairs algorithmic discovery with experienced clinical teams.